CTOs on the Move

Kaiser Inc

www.kaiser.com

 
Kaiser Inc is a Manteca, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.kaiser.com
  • 2510 W Yosemite Ave Floor
    Manteca, CA USA 95337
  • Phone: 505.746.6393

Executives

Name Title Contact Details

Similar Companies

Clinical Research Consultants

Clinical Research Consultants is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Public Health Company

PHC empowers organizations to proactively manage infectious disease risk through global disease forecasting, risk analysis, and practical guidance. PHC was founded by Dr. Charity Dean, and employs a world-class team of public health professionals, tech...

MGI PHARMA

MGI PHARMA, Inc. is a Lake Villa, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Protagonist Therapeutics

Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.